跳至主要内容
临床试验/NCT00809731
NCT00809731
已完成
不适用

A Naturalistic Observational Study to Evaluate Efficacy of 2nd-generation Antipsychotics and Remission Status for Patients With Schizophrenia / Schizoaffective Disorder

AstraZeneca1 个研究点 分布在 1 个国家目标入组 490 人开始时间: 2008年12月最近更新:
适应症Schizophrenia

概览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
490
试验地点
1
主要终点
CGI-Severity of illness (CGI-SI)

概览

简要总结

The objective of this study is to evaluate under routine clinical setting the efficacy and remission status from treatment of 2nd-generation antipsychotic in patients who is upon acute episode or not achieving remission under regular treatment from schizophrenia/schizoaffective disorder. This study will collect in real-life practice the severity of schizophrenia by Clinical Global Impression (CGI), also evaluate the criteria of schizophrenia remission applying 8 items of Positive and Negative Syndrome Scale (PANSS) from Andresen working group, the Montgomery and Asberg Depression Rating Scale (MADRS), and the Global Assessment of Functioning Scale (GAF). Side effect of movement disorder will be evaluated by Drug Induced Extrapyramidal Symptoms Scale (DIEPSS). Tolerability for treatment will be monitored by documenting spontaneous reports on adverse events as well as change in body weight.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with acute episode (first or relapse), or upon revisit and identified not achieving remission of schizophrenia or schizoaffective disorder (according to remission criteria of schizophrenia)
  • Male or female aged between 18 and 65 years
  • Patients recruited from both in-patient and out-patient clinics
  • Patients who are cooperative, by judgment from investigators, and the use of oral antipsychotic considered adequate

排除标准

  • Pregnancy or lactation
  • Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
  • Known intolerance, lack of response, or contraindication to prescribed atypical antipsychotic, as judged by the investigator
  • Administration of a depot antipsychotic injection within one dosing interval (for the depot) before enrolment and patients prescribed with clozapine within 3 months prior to enrolment

结局指标

主要结局

CGI-Severity of illness (CGI-SI)

时间窗: Visit 1(Day 0), 2(Day 3), 3(Week 1), 4(Week 2), 5(Week 4)

次要结局

  • CGI-Degree of change (CGI-DC)(Visit 2(Day 3), 3(Week 1), 4(Week 2), 5(Week 4))
  • MADRS, GAF, DIEPSS(Visit 1(Day 0), 2(Day 3), 3(Week 1), 4(Week 2), 5(Week 4))
  • Remission status(Visit 1(Day 0), 5(Week 4))

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验